Marksans Pharma Limited announces UK MHRA approval for Loperamide 2mg Hard Capsules

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has announced that UK MHRA has granted Market Authorisation to the Company's wholly owned subsidiary Relonchem Limited for Loperamide 2mg Hard Capsules.

Marksans will manufacture the products at its UK MHRA approved state-of-the-art oral dosage facility located at Goa, India.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 59.85 as compared to the previous close of Rs. 58.70. The total number of shares traded during the day was 225473 in over 1867 trades.

The stock hit an intraday high of Rs. 60.70 and intraday low of 58.75. The net turnover during the day was Rs. 13546939.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Pharmaceuticals UKMHRA MarketAuthorisation Relonchem Loperamide